查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1810972

2025年神经基因体学全球市场报告

Neurogenomics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年神经基因组学市场将快速成长，到 2029 年将达到 26 亿美元，复合年增长率为 14.7%。预测期内的增长可归因于人们对心理健康个性化治疗的兴趣日益浓厚、直接面向消费者的神经遗传学检测的使用日益增多、多体学方法的采用日益增多、精准神经病学倡议的不断扩展以及标靶治疗的使用日益增多。在此期间，预计的主要趋势包括人工智慧基因组分析的发展、非侵入性诊断平台的演变、多体学技术的整合、基因组学与精准神经病学的结合以及神经退化性疾病建模的创新。

神经系统疾病盛行率的上升预计将在未来几年推动神经基因组学市场的成长。神经系统疾病是一种影响大脑、脊髓和神经的疾病，会导致肌肉无力、癫痫、慢性疼痛和认知障碍等症状。盛行率的上升主要是由于生活方式相关因素，例如不良饮食、缺乏运动、慢性压力以及环境毒素暴露增加。神经基因组学在治疗这些疾病方面发挥关键作用，它能深入了解大脑功能和功能障碍的遗传基础，从而改善诊断、找出根本原因并实现有针对性的治疗。例如，2023 年 3 月，阿兹海默症症协会报告称，约有 670 万 65 岁及以上的美国人患有老年痴呆症失智症。预计到 2060 年，这一数字将增加到 1,380 万。因此，神经系统疾病盛行率的上升正在促进神经基因组学市场的扩张。

神经基因组学市场的主要企业专注于最尖端科技，例如全基因组定序平台，以改善对罕见和复杂神经系统疾病的诊断和理解。全基因定序平台分析个别基因组的完整 DNA 序列，有助于识别与神经系统疾病相关的遗传因子。例如，2023 年 4 月，专门研究罕见疾病的德国诊断和研究公司 Centogene NV 推出了 CentoGenome，这是全球最全面的诊断罕见和神经退化性疾病的全基因组定序 (WGS) 解决方案。该平台采用非 PCR 技术进行高品质、无偏差定序，尤其是在难以定序的基因区域。先进的生物资讯流程和专家分析可改善变异检测，在一次测试中捕捉几乎所有致病变异。该服务还包括终身综合诊断支持，如果发现新的遗传发现，则提供免费的变异重新分类和确认测试。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球神经基因组学：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球神经基因体学市场：成长率分析
  • 全球神经基因组学市场表现：规模与成长，2019-2024
  • 全球神经基因组学市场预测：规模与成长，2024-2029 年，2034 年
  • 全球神经基因体学：总潜在市场（TAM）

第六章市场区隔

  • 全球神经基因体学市场：依产品、实际状况及预测，2019-2024 年、2024-2029 年、2034 年
  • 次世代定序
  • 聚合酵素链锁反应
  • 微阵列
  • 软体和服务
  • 全球神经基因体学市场：依应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 突变体的发现
  • 调查应用
  • 目标识别
  • 转录因子结合分析
  • 功能研究
  • 临床应用
  • 全球神经基因组学市场：按最终用户、实际和预测，2019-2024 年、2024-2029 年、2034 年
  • 製药和生物技术公司
  • 学术研究机构
  • 医院和诊断实验室
  • 全球神经基因体学市场：依次世代定序（按类型）、实际与预测，2019-2024 年、2024-2029 年、2034 年
  • 全基因组序列分析
  • 全EXOME定序
  • 标靶定序
  • 核糖核酸序列分析
  • 全球神经基因体学市场：聚合酵素链锁反应（按类型）、实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 即时聚合酵素链锁反应
  • 逆转录聚合酵素链锁反应
  • 数位聚合酵素链锁反应
  • 全球神经基因组学市场：按微阵列类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 去氧核糖核酸微阵列
  • 核糖核酸微阵列
  • 蛋白质微阵列
  • 全球神经基因组学市场：按软体和服务细分（按类型）、实际和预测，2019-2024 年、2024-2029 年、2034 年
  • 数据分析与解释软体
  • 基因组资料管理工具
  • 客製化服务
  • 云端基础的平台和报告工具

第七章 区域和国家分析

  • 全球神经基因体学市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球神经基因体学市场：依国家/地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 神经基因体学市场：竞争格局
  • 神经基因组学市场：公司简介
    • F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Agilent Technologies Inc.
  • Illumina Inc.
  • Revvity Inc.
  • QIAGEN NV
  • Myriad Genetics Inc.
  • GeneDx LLC
  • Fulgent Genetics Inc.
  • Oxford Nanopore Technologies Plc
  • Vigil Neuroscience Inc.
  • PacBio
  • MedGenome Labs Ltd.
  • MGI Tech Co. Ltd.
  • Centogene NV
  • Variantyx Inc.
  • Neurogene

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年神经基因体学市场：提供新机会的国家
  • 2029年神经基因体学市场：细分领域带来新机会
  • 2029年神经基因体学市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r37074

Neurogenomics is the study of how the genome affects the development and function of the nervous system, integrating neuroscience and genomics to better understand brain-related diseases, behavior, and cognition. Through the analysis of gene expression and genetic variations, researchers aim to uncover the underlying mechanisms of neurological disorders, advancing personalized medicine approaches in neurology.

The primary offerings in neurogenomics include next-generation sequencing (NGS), polymerase chain reaction (PCR), microarrays, and related software and services. Next-generation sequencing is a high-throughput DNA sequencing technology that enables the rapid and parallel analysis of millions of DNA fragments to determine their precise sequence. These technologies support a wide array of applications, including variant discovery, research studies, target identification, transcription factor binding analysis, functional genomics, and clinical diagnostics. Key end users include pharmaceutical and biotechnology companies, academic and research institutions, and hospitals and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The neurogenomics market research report is one of a series of new reports from The Business Research Company that provides neurogenomics market statistics, including neurogenomics global market size, regional shares, competitors with neurogenomics market share, detailed neurogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the neurogenomics industry. The neurogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurogenomics market size has grown rapidly in recent years. It will grow from $1.31 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. Growth during the historic period can be attributed to the rising demand for genetic testing in neurological disorders, increased research on the connections between the brain, behavior, and genome, the growing prevalence of neurodegenerative diseases, increased funding for neuroscience research, and the expansion of biobanks and genomic databases.

The neurogenomics market size is expected to see rapid growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. Growth in the forecast period can be attributed to the rising interest in personalized treatments for mental health, increased use of direct-to-consumer neurogenetic testing, growing adoption of multi-omics approaches, expansion of precision neurology initiatives, and greater use of targeted therapies. Key trends expected during this period include the development of artificial intelligence-powered genomic analytics, advancements in non-invasive diagnostic platforms, integration of multi-omics technologies, incorporation of genomics into precision neurology, and innovations in modeling neurodegenerative diseases.

The rising prevalence of neurological disorders is expected to drive the growth of the neurogenomics market in the coming years. Neurological disorders are medical conditions that impact the brain, spinal cord, or nerves and can cause symptoms such as muscle weakness, seizures, chronic pain, or cognitive impairments. This increase in prevalence is largely attributed to lifestyle-related factors, including poor dietary habits, insufficient physical activity, chronic stress, and greater exposure to environmental toxins. Neurogenomics plays a crucial role in addressing these disorders by offering insights into the genetic underpinnings of brain function and dysfunction, thereby improving diagnosis, identifying root causes, and enabling targeted treatments. For example, in March 2023, the Alzheimer's Association reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia. This figure is projected to increase to 13.8 million by 2060. Thus, the growing incidence of neurological disorders is contributing to the expansion of the neurogenomics market.

Leading companies in the neurogenomics market are focusing on developing cutting-edge technologies such as whole genome sequencing platforms to improve the diagnosis and understanding of rare and complex neurological conditions. Whole genome sequencing platforms analyze the complete DNA sequence of an individual's genome and are instrumental in identifying genetic factors linked to neurological disorders. For instance, in April 2023, Centogene N.V., a Germany-based diagnostics and research company specializing in rare diseases, introduced CentoGenome, the world's most comprehensive whole-genome sequencing (WGS) solution for diagnosing rare and neurodegenerative conditions. This platform incorporates PCR-free technology for high-quality, unbiased sequencing, particularly across difficult-to-sequence genetic regions. It improves variant detection through a sophisticated bioinformatics pipeline and expert analysis, capturing nearly all disease-causing variants in a single test. The service also includes integrated, lifelong diagnostic support, with free variant reclassification and confirmatory testing as new genetic insights emerge.

In February 2025, Tempus AI Inc., a US-based health technology company, acquired Ambry Genetics for $600 million. This acquisition was intended to enhance Tempus AI's precision medicine platform by incorporating Ambry Genetics' specialized capabilities in hereditary and clinical genetic testing. The integration broadens Tempus AI's reach across various therapeutic areas, including oncology, cardiology, rare diseases, and neurological conditions. Ambry Genetics Corporation, a US-based genetic testing company, provides neurogenomics services through a wide array of genetic testing options for neurological and neurodevelopmental disorders.

Major players in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc., Vigil Neuroscience Inc., PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., and Neurogene.

North America was the largest region in the neurogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurogenomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurogenomics market consists of revenues earned by entities by providing services such as genomic sequencing services, bioinformatics and data analysis, research and clinical trial support, customized gene panel development, and pharmacogenomics services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurogenomics market also includes sales of genomic sequencing kits, microarray chips, bioinformatics software, neurogenomic biomarkers, and single-cell genomics kits. Values in this market are 'factory gate' values that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurogenomics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurogenomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurogenomics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurogenomics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Offering: Next-Generation Sequencing; Polymerase Chain Reaction; Microarray; Software And Services
  • 2) By Application: Variant Discovery; Research Applications; Target Identification; Transcription Factor Binding Analysis; Functional Studies; Clinical Applications
  • 3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Hospitals And Diagnostic Laboratories
  • Subsegments:
  • 1) By Next-Generation Sequencing: Whole Genome Sequencing; Whole Exome Sequencing; Targeted Sequencing; Ribonucleic Acid Sequencing
  • 2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction; Reverse Transcription Polymerase Chain Reaction; Digital Polymerase Chain Reaction
  • 3) By Microarray: Deoxyribonucleic Acid Microarray; Ribonucleic Acid Microarray; Protein Microarray
  • 4) By Software And Services: Data Analysis And Interpretation Software; Genomic Data Management Tools; Custom Services; Cloud-Based Platforms And Reporting Tools
  • Companies Mentioned: F. Hoffmann-La Roche Limited; Thermo Fisher Scientific Incorporated; Danaher Corporation; Quest Diagnostics Incorporated; Eurofins Scientific SE; Agilent Technologies Inc.; Illumina Inc.; Revvity Inc.; QIAGEN N.V.; Myriad Genetics Inc.; GeneDx LLC; Fulgent Genetics Inc.; Oxford Nanopore Technologies Plc; Vigil Neuroscience Inc.; PacBio; MedGenome Labs Ltd.; MGI Tech Co. Ltd.; Centogene N.V.; Variantyx Inc.; Neurogene.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurogenomics Market Characteristics

3. Neurogenomics Market Trends And Strategies

4. Neurogenomics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurogenomics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neurogenomics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neurogenomics Market Growth Rate Analysis
  • 5.4. Global Neurogenomics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neurogenomics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neurogenomics Total Addressable Market (TAM)

6. Neurogenomics Market Segmentation

  • 6.1. Global Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Microarray
  • Software And Services
  • 6.2. Global Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Variant Discovery
  • Research Applications
  • Target Identification
  • Transcription Factor Binding Analysis
  • Functional Studies
  • Clinical Applications
  • 6.3. Global Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmaceutical And Biotechnology Companies
  • Academic And Research Institutes
  • Hospitals And Diagnostic Laboratories
  • 6.4. Global Neurogenomics Market, Sub-Segmentation Of Next-Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing
  • Ribonucleic Acid Sequencing
  • 6.5. Global Neurogenomics Market, Sub-Segmentation Of Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcription Polymerase Chain Reaction
  • Digital Polymerase Chain Reaction
  • 6.6. Global Neurogenomics Market, Sub-Segmentation Of Microarray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Deoxyribonucleic Acid Microarray
  • Ribonucleic Acid Microarray
  • Protein Microarray
  • 6.7. Global Neurogenomics Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Analysis And Interpretation Software
  • Genomic Data Management Tools
  • Custom Services
  • Cloud-Based Platforms And Reporting Tools

7. Neurogenomics Market Regional And Country Analysis

  • 7.1. Global Neurogenomics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neurogenomics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurogenomics Market

  • 8.1. Asia-Pacific Neurogenomics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurogenomics Market

  • 9.1. China Neurogenomics Market Overview
  • 9.2. China Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurogenomics Market

  • 10.1. India Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurogenomics Market

  • 11.1. Japan Neurogenomics Market Overview
  • 11.2. Japan Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurogenomics Market

  • 12.1. Australia Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurogenomics Market

  • 13.1. Indonesia Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurogenomics Market

  • 14.1. South Korea Neurogenomics Market Overview
  • 14.2. South Korea Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurogenomics Market

  • 15.1. Western Europe Neurogenomics Market Overview
  • 15.2. Western Europe Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurogenomics Market

  • 16.1. UK Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurogenomics Market

  • 17.1. Germany Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurogenomics Market

  • 18.1. France Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurogenomics Market

  • 19.1. Italy Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurogenomics Market

  • 20.1. Spain Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurogenomics Market

  • 21.1. Eastern Europe Neurogenomics Market Overview
  • 21.2. Eastern Europe Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurogenomics Market

  • 22.1. Russia Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurogenomics Market

  • 23.1. North America Neurogenomics Market Overview
  • 23.2. North America Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurogenomics Market

  • 24.1. USA Neurogenomics Market Overview
  • 24.2. USA Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurogenomics Market

  • 25.1. Canada Neurogenomics Market Overview
  • 25.2. Canada Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurogenomics Market

  • 26.1. South America Neurogenomics Market Overview
  • 26.2. South America Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurogenomics Market

  • 27.1. Brazil Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurogenomics Market

  • 28.1. Middle East Neurogenomics Market Overview
  • 28.2. Middle East Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurogenomics Market

  • 29.1. Africa Neurogenomics Market Overview
  • 29.2. Africa Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurogenomics Market Competitive Landscape And Company Profiles

  • 30.1. Neurogenomics Market Competitive Landscape
  • 30.2. Neurogenomics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis

31. Neurogenomics Market Other Major And Innovative Companies

  • 31.1. Agilent Technologies Inc.
  • 31.2. Illumina Inc.
  • 31.3. Revvity Inc.
  • 31.4. QIAGEN N.V.
  • 31.5. Myriad Genetics Inc.
  • 31.6. GeneDx LLC
  • 31.7. Fulgent Genetics Inc.
  • 31.8. Oxford Nanopore Technologies Plc
  • 31.9. Vigil Neuroscience Inc.
  • 31.10. PacBio
  • 31.11. MedGenome Labs Ltd.
  • 31.12. MGI Tech Co. Ltd.
  • 31.13. Centogene N.V.
  • 31.14. Variantyx Inc.
  • 31.15. Neurogene

32. Global Neurogenomics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurogenomics Market

34. Recent Developments In The Neurogenomics Market

35. Neurogenomics Market High Potential Countries, Segments and Strategies

  • 35.1 Neurogenomics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neurogenomics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neurogenomics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer